Blinatumomab Added to Interfant-06 Chemotherapy “Safe and Efficacious” in Infants with Newly Diagnosed KMT2A-Rearranged ALL

06.09.23

Blinatumomab Added to Interfant-06 Chemotherapy “Safe and Efficacious” in Infants with Newly Diagnosed KMT2A-Rearranged ALL

by Eleanor Mayfield, ELS

EAT It Up: In Preclinical Study, VEGF Blockade “Significantly Improves” Efficacy of Ex Vivo Armed T-Cells

05.11.23

EAT It Up: In Preclinical Study, VEGF Blockade “Significantly Improves” Efficacy of Ex Vivo Armed T-Cells

by Eleanor Mayfield, ELS

In Multiple Myeloma, T-Cell Response to TCEs “Is Determined by Pre-Existing Cell State”

05.09.23

In Multiple Myeloma, T-Cell Response to TCEs “Is Determined by Pre-Existing Cell State”

by Eleanor Mayfield, ELS

In MajesTEC-1 Trial, Tocilizumab Reduced Recurrent CRS in Patients Treated with Teclistamab for RRMM

05.04.23

In MajesTEC-1 Trial, Tocilizumab Reduced Recurrent CRS in Patients Treated with Teclistamab for RRMM

by Eleanor Mayfield, ELS

Study Provides First Preclinical Evidence of a Bispecific Trifunctional Antibody–Induced Anti-Tumor Vaccination Effect in Neuroblastoma

03.07.23

Study Provides First Preclinical Evidence of a Bispecific Trifunctional Antibody–Induced Anti-Tumor Vaccination Effect in Neuroblastoma

by Eleanor Mayfield, ELS

Oncolytic Adenovirus-Armed BiTEs “Could Overcome Limitations of BiTEs in Treatment of Solid Tumors”

03.03.23

Oncolytic Adenovirus-Armed BiTEs “Could Overcome Limitations of BiTEs in Treatment of Solid Tumors”

by Eleanor Mayfield, ELS

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

01.30.23

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

by Eleanor Mayfield, ELS

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

01.13.23

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

by Eleanor Mayfield, ELS

Small Study Finds Blinatumomab/Dasatinib Combination “Safe and Feasible” in Patients Aged Over 65 with Ph+ ALL

01.10.23

Small Study Finds Blinatumomab/Dasatinib Combination “Safe and Feasible” in Patients Aged Over 65 with Ph+ ALL

by Eleanor Mayfield, ELS

Theme picker